drugset
Drugs / pUMVC3-hIGFBP-2 Multi-Epitope Plasmid DNA Vaccine
last change 2 days ago re-read 3 minutes ago

pUMVC3-hIGFBP-2 Multi-Epitope Plasmid DNA Vaccine

Vaccine

Developed for
ovarian carcinoma · primary peritoneal carcinoma · fallopian tube cancer
Investigated by
University of Washington · National Cancer Institute (NCI) · The Wayne D. Kuni and Joan E. Kuni Foundation

Trials 2

today NCT07495124 · Ph 2 NCT03029611 · Ph 2
201720182019202020212022202320242025202620272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT07495124 Oct 2026 → Sep 2027 expected fallopian tube carcinoma, ovarian carcinoma, primary peritoneal carcinoma University of Washington Not yet recruiting No outcome recorded
Phase 2 NCT03029611 Apr 2017 → Oct 2018 fallopian tube cancer, ovarian carcinoma, primary peritoneal carcinoma University of Washington Terminated No outcome recorded Stop: Business

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as pUMVC3-hIGFBP-2 Multi-Epitope Plasmid DNA Vaccine ClinicalTrials.gov intervention name — accepted as the source's own label NCT03029611 ↗
1

NCT07495124 ↗
Modality Vaccine “pUMVC3-IGFBP2 plasmid deoxyribonucleic acid (DNA) vaccine” NCT03029611 ↗